Opinion: Chinese CDMOs and US Biopharma PR Strike a Precarious Balance

The PR departments of Chinese CDMOs affected by the BIOSECURE Act and their U.S. partners must step up to ensure proposed legislation doesn’t squash innovation.

Scroll to Top